Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· North Texas Medical Anti Aging CenterAudio language not provided

FASTING IN A PILL? HOW SGLT2 INHIBITORS ARE "TRICKING" BIOLOGY INTO STAYING YOUNG

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

About this video

Creator description · original textText language: English

For years, SGLT2 inhibitors (like Jardiance and Farxiga) were known simply as tools to help the body flush excess sugar through the urine. But as of 2026, the narrative has shifted completely. What was once a "diabetes drug" is now being recognized as one of the most potent tools in the geroscience toolkit. The Evidence: Beyond Glucose Control Massive Randomized Controlled Trials (RCTs) like EMPA-REG and DAPA-HF delivered a shock to the medical community. The data showed that these drugs don’t just lower blood sugar—they provide significant protection for the heart and kidneys, even in people without diabetes. Why are longevity specialists increasingly prescribing these "off-label" to healthy adults? • The Fasting Mimetic: SGLT2 inhibitors essentially "trick" the body into a state that mimics caloric restriction and fasting. By lowering insulin levels and shifting the body toward fat oxidation, they trigger cellular repair pathways similar to those found in long-lived populations. • All-Cause Mortality: The reduction in mortality across these trials was so consistent that many researchers believe we are looking at a true "geroprotector"—a compound that slows the underlying processes of aging itself. In massive clinical trials and recent meta-analyses, SGLT2 inhibitors have demonstrated a consistent and significant reduction in all-cause mortality (death from any cause), even among patients without diabetes. • The reduction ranged from 13% to 32%, depending on the specific patient population (e.g., those with heart failure, kidney disease, or high cardiovascular risk). • • Organ Protection: The placebo-controlled data on heart failure prevention and kidney preservation is now considered overwhelming by the clinical community. We are entering an era of "Precision Longevity," where we use validated pharmaceutical tools to mimic the survival signals of our ancestors. SGLT2 inhibitors represent a bridge between managing a disease and actively engineering a longer, healthier life.

North Texas Medical Anti Aging Center · 3 min · Source published: 2026-03-05

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…